Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

18.69
+0.63003.49%
Post-market: 18.800.1100+0.59%19:30 EDT
Volume:773.27K
Turnover:14.36M
Market Cap:1.11B
PE:1.62
High:18.99
Open:18.09
Low:18.09
Close:18.06
52wk High:39.49
52wk Low:6.50
Shares:59.16M
Float Shares:37.23M
Volume Ratio:0.77
T/O Rate:2.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):11.53
EPS(LYR):-70.5015
ROE:-125.43%
ROA:-21.37%
PB:-5.52
PE(LYR):-0.27

Loading ...

U.S. Stocks on the MOVE-Snowflake, Cboe, Oracle

Reuters
·
Sep 29

US Stocks on the MOVE-Veracyte, Staar Surgical, Corning

Reuters
·
Sep 29

Vor Biopharma Rises After Positive Autoimmune Drug Data

Reuters
·
Sep 29

Vor Bio Says Telitacicept Phase 3 Analysis Shows 42% Minimal Symptom Expression in gMG Through 48 Weeks

Reuters
·
Sep 29

Vor Biopharma Inc: More than 94% of Participants Achieved a ≥5-Point Mg-Adl Improvement at Week 48

THOMSON REUTERS
·
Sep 29

Vor Biopharma Inc: Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

Vor Biopharma Inc: Telitacicept was Generally Well Tolerated Through 48 Weeks with no New Safety Signals Observed

THOMSON REUTERS
·
Sep 29

Vor Biopharma (VOR) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
Sep 28

Citi Keeps Their Buy Rating on Vor Biopharma (VOR)

TIPRANKS
·
Sep 10

Vor Bio completes enrollment in UPSTREAM MG trial

TIPRANKS
·
Sep 08

Vor Bio Completes Enrollment in Phase 3 Upstream MG Trial for Telitacicept in Generalized Myasthenia Gravis

Reuters
·
Sep 08

Vor Completes Enrollment of Global Phase 3 Upstream Mg Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

THOMSON REUTERS
·
Sep 08

Vor Biopharma - Upstream Mg 24-Week Primary Endpoint Results Expected in First Half of 2027

THOMSON REUTERS
·
Sep 08

Vor Bio files automatic mixed securities shelf

TIPRANKS
·
Sep 05

Vor Biopharma Inc. - Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Sep 05

Vor Bio Grants 83,600 Stock Options, 17,900 RSUs to New Hires Under Inducement Plan

Reuters
·
Sep 05

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Aug 31

Citi Remains a Buy on Vor Biopharma (VOR)

TIPRANKS
·
Aug 13

Vor Biopharma is Maintained at Neutral by Wedbush

Dow Jones
·
Aug 13

Vor Biopharma (VOR) Receives a Hold from Wedbush

TIPRANKS
·
Aug 12